MedTrace Logo

SUBA-Itraconazole Therapy for Coccidioidomycosis Refractory or Intolerant to Fluconazole

NCT04809649 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2021-07-19

No results posted yet for this study

Summary

The purpose of this study is to determine how safe, effective, and well tolerated a new investigational antifungal drug, SUBA-itraconazole, is for patients who have been previously treated with fluconazole and have had either an insufficient response to treatment with fluconazole or a negative reaction to fluconazole preventing their further treatment with it.

Conditions

  • Coccidioidomycosis
  • Valley Fever

Interventions

DRUG

SUBA-itraconazole

Participant will receive treatment with SUBA-itraconazole

Sponsors & Collaborators

  • Mayne Pharma International Pty Ltd

    collaborator INDUSTRY

  • George R Thompson

    lead OTHER

Principal Investigators

  • George R Thompson, MD · University of California, Davis

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-15
Primary Completion
2022-09-30
Completion
2022-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04809649 on ClinicalTrials.gov